S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
BABA   186.97 (+0.14%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
BAC   33.09 (-0.27%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
BABA   186.97 (+0.14%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
BAC   33.09 (-0.27%)
DIS   138.58 (+1.35%)
Log in

Cerus Stock Price, Forecast & Analysis (NASDAQ:CERS)

$4.28
+0.19 (+4.65 %)
(As of 11/12/2019 04:00 PM ET)
Today's Range
$4.05
Now: $4.28
$4.36
50-Day Range
$4.11
MA: $4.56
$5.33
52-Week Range
$3.95
Now: $4.28
$6.88
Volume1.32 million shs
Average Volume866,396 shs
Market Capitalization$600.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.91 million
Book Value$0.62 per share

Profitability

Net Income$-57,560,000.00
Net Margins-100.38%

Miscellaneous

Employees240
Market Cap$600.58 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.


Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The biotechnology company earned $18 million during the quarter, compared to analyst estimates of $17.69 million. Cerus had a negative return on equity of 100.59% and a negative net margin of 100.38%. Cerus's quarterly revenue was up 16.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.11) EPS. View Cerus' Earnings History.

When is Cerus' next earnings date?

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cerus.

What price target have analysts set for CERS?

3 equities research analysts have issued 1 year target prices for Cerus' shares. Their forecasts range from $7.00 to $9.00. On average, they expect Cerus' share price to reach $8.00 in the next year. This suggests a possible upside of 86.9% from the stock's current price. View Analyst Price Targets for Cerus.

What is the consensus analysts' recommendation for Cerus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

Has Cerus been receiving favorable news coverage?

News stories about CERS stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cerus earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Cerus.

Are investors shorting Cerus?

Cerus saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 7,090,000 shares, a decline of 5.6% from the August 30th total of 7,510,000 shares. Based on an average daily volume of 859,900 shares, the days-to-cover ratio is currently 8.2 days. Currently, 5.3% of the company's stock are sold short. View Cerus' Current Options Chain.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Who are Cerus' key executives?

Cerus' management team includes the folowing people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (6.09%), Sumitomo Mitsui Trust Holdings Inc. (6.09%), Peregrine Capital Management LLC (1.44%), Stephens Inc. AR (0.67%), First Midwest Bank Trust Division (0.60%) and Lesa Sroufe & Co (0.33%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Which major investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Sepio Capital LLC, Peregrine Capital Management LLC, First Midwest Bank Trust Division, Lesa Sroufe & Co and Salzhauer Michael. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Which major investors are buying Cerus stock?

CERS stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Strategic Wealth Advisors Group LLC, Stephens Inc. AR, Janney Montgomery Scott LLC and Raymond James Trust N.A.. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash and William Mariner Greenman. View Insider Buying and Selling for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $4.28.

How big of a company is Cerus?

Cerus has a market capitalization of $600.58 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

What is Cerus' official website?

The official website for Cerus is http://www.cerus.com/.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (NASDAQ CERS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  503 (Vote Outperform)
Underperform Votes:  348 (Vote Underperform)
Total Votes:  851
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel